Getting To Grips With International Reference Pricing
International reference pricing has become something of a fixture as payers around the world grapple with rising healthcare costs. The landscape is becoming more complex as the practice spreads further into emerging markets, reference baskets get bigger, and calls for pricing transparency grow louder. Scrip examines some of the problems companies face and some of the ways they can adapt, including through new technology, revised approaches to launching new products and better relations with stakeholders.
You may also be interested in...
A committee of influential politicians in Europe are calling for measures that will see the EU become more self-sufficient in the production of medicines, thereby reducing medicine shortages and dependence on imports from third countries.
In a “strengthened call to action” to improve access to medicines, the European Patients Forum says an EU-level reflection on differential pricing is needed and that patients should to be more central to designing R&D.
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.